Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi Sells 8,612 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 8,612 shares of the firm’s stock in a transaction on Wednesday, January 12th. The shares were sold at an average price of $52.08, for a total value of $448,512.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nello Mainolfi also recently made the following trade(s):

  • On Monday, January 10th, Nello Mainolfi sold 22,465 shares of Kymera Therapeutics stock. The shares were sold at an average price of $53.26, for a total value of $1,196,485.90.

Shares of KYMR stock opened at $41.07 on Friday. The stock has a market capitalization of $2.11 billion, a PE ratio of -24.30 and a beta of 1.36. Kymera Therapeutics, Inc. has a 52-week low of $29.93 and a 52-week high of $87.49. The stock’s 50-day moving average price is $57.41 and its 200 day moving average price is $57.66.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Wednesday, November 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.19). The company had revenue of $20.34 million during the quarter, compared to analyst estimates of $20.18 million. Kymera Therapeutics had a negative net margin of 112.31% and a negative return on equity of 24.30%. As a group, equities research analysts predict that Kymera Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Dark Forest Capital Management LP boosted its holdings in Kymera Therapeutics by 3,292.0% in the 3rd quarter. Dark Forest Capital Management LP now owns 848 shares of the company’s stock valued at $50,000 after purchasing an additional 823 shares in the last quarter. O Shaughnessy Asset Management LLC purchased a new stake in Kymera Therapeutics in the 3rd quarter valued at approximately $64,000. Wells Fargo & Company MN boosted its holdings in Kymera Therapeutics by 60.9% in the 2nd quarter. Wells Fargo & Company MN now owns 1,430 shares of the company’s stock valued at $69,000 after purchasing an additional 541 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in Kymera Therapeutics in the 2nd quarter valued at approximately $73,000. Finally, First Mercantile Trust Co. boosted its holdings in Kymera Therapeutics by 47.3% in the 2nd quarter. First Mercantile Trust Co. now owns 1,728 shares of the company’s stock valued at $84,000 after purchasing an additional 555 shares in the last quarter. 67.32% of the stock is currently owned by institutional investors.

A number of research firms have recently commented on KYMR. Stifel Nicolaus began coverage on Kymera Therapeutics in a research report on Wednesday, September 29th. They set a “buy” rating and a $80.00 target price on the stock. Brookline Capital Acquisition began coverage on Kymera Therapeutics in a research report on Wednesday, October 13th. They set a “buy” rating and a $80.00 target price on the stock. B. Riley began coverage on Kymera Therapeutics in a research report on Thursday, September 30th. They set a “neutral” rating and a $67.00 target price on the stock. They noted that the move was a valuation call. Brookline Capital Management reiterated a “buy” rating and set a $80.00 target price on shares of Kymera Therapeutics in a research report on Wednesday, October 13th. Finally, Zacks Investment Research cut Kymera Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $76.00.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases.

Recommended Story: How can investors invest in the S&P/TSX Index?

Insider Buying and Selling by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.